Blood Pressure Chart | Lower your High Blood Pressure Naturally » 2010

Chile Mine Rescue, Franklin Lobos 13th October 2010

Wed, 03 Nov 2010 01:12:55 +0000

27th Miner Franklin Lobos emerges into daylight for the first time in 69 days, and comes to an emotional reunion with his daughter. In this video you can see the president of Chile greeting all the miners as they come out, one by one, and you can see how they are been saved Luis Urzua, 54 The shift foreman, known as Don Lucho by other miners, took a leading role while they were trapped and made maps of their cave. Descriptions of the Miners: Yonni Barrios, 50 Known as “the doctor” because he has first aid skills from helping his diabetic mother. While he has been underground his wife discovered he had a girlfriend. Franklin Lobos, 53 A well known former football player known as the “magic mortar.” While underground he received a T-shirt signed by Barcelona player David Villa. Mario Sepulveda, 40 An electrical specialist known as “the presenter” because he acted as a spokesman and guide on videos the miners sent up. He ended one video saying “Over to you in the studio.” Raul Bustos, 40 The hydraulics engineer was a victim of the February earthquake in Chile. He moved north, finding work at the mine to support his wife and two children. Ariel Ticona, 29 His wife gave birth to a daughter on Sept 14 and he was able to watch the arrival on video. He named her Esperanza, which means “hope.” Daniel Herrera, 27 Truck driver was given the role of medical assistant in the mine. He complained about the psychologist dealing with the men, saying it was causing hysteria. Florencio …

Relevant Resources

Cardiovascular Risk with Meridia (April 2010)

Thu, 16 Sep 2010 19:14:32 +0000

FDA is alerting healthcare professionals that Meridia (sibutramine) is contraindicated in patients with a history of cardiovascular disease because the drug increases their risk of heart attack and stroke. Meridia is used to manage obesity. In November 2009, an early communication from FDA reported preliminary study results suggesting that patients on Meridia had a greater frequency of cardiovascular events than those not taking the drug. Additional data from the study has shown that the excess risk occurred in patients with a history of cardiovascular disease. Based on this information, Meridia is now contraindicated in patients with a history of cardiovascular disease, including coronary artery disease, stroke or transient ischemic attack (TIA), cardiac arrhythmias, congestive heart failure, peripheral arterial disease, or uncontrolled hypertension. Healthcare professionals should regularly monitor the blood pressure and heart rate of patients using Meridia and discontinue the drug if there are sustained increases in these measurements. They should also discontinue Meridia in patients who do not lose at least 5 percent of their baseline body weight within the first three to six months of treatment, because further treatment is not likely to be effective and exposes the patient to unnecessary risk. Patients using Meridia should talk with their healthcare professional about whether to continue using the drug.

Relevant Resources

FINAL EXAM Case 13 Due May 3, 2010

Tue, 07 Sep 2010 11:12:28 +0000

FINAL EXAM Case 13 Due May 3, 2010 Case 13 1.The diagnosis for the UPPER LEFT case is mitral valve: A.Stenosis B.Prolapse C.Flail D.Vegetation (infective endocarditis) 2.The segmental wall motion abnormality (SWMA) is located (UPPER RIGHT): A.Anterior IVS B.Inferolateral (posterior) wall of the LV 3.For the LOWER LEFT screen, there is LAE and LVH present. The differential diagnosis would include all of the following EXCEPT: A.Aortic stenosis (AS) B.Systemic hypertension C.Pulmonary hypertension D.Chronic renal failure (CRF) E.Cardiac amyloidosis 4.The LOWER RIGHT screen is demonstrating mitral valve: A.Stenosis B.Prolapse C.Flail D.Normal

Relevant Resources

“Making Chronic Conditions Count” report launch (March 2010)

Sun, 25 Jul 2010 10:13:51 +0000

An interview with Prof Kevin Balanda of the Institute of Public Health in Ireland at the launch of the “Making Chronic Conditions Count” report launch (March 2010). The report describes the distribution of four chronic conditions (hypertension, coronary heart disease, stroke and diabetes) across the island of Ireland and how it is expected to change between 2007 and 2020. Its findings highlight the need for a greater emphasis on prevention and tackling health inequalties. If the “social determinants of health – poverty, unemployment, low income, poor education, inadquate housing, etc – are not addressed we can expect little further success in either of these endeavours.

Relevant Resources

PH Video Journey 2010 – Amanda McKee

Sat, 24 Jul 2010 13:12:21 +0000

Relevant Resources

Pulmo BioTech Inc. Announces Attendance at RSNA 2010

Thu, 08 Jul 2010 05:13:00 +0000

Pulmo BioTech Inc. Announces Attendance at RSNA 2010
NEW YORK — Pulmo BioTech Inc. announces that later this year it intends to exhibit at RSNA 2010, the 96th Scientific Assembly & Annual Meeting of the Radiological Society of North America, which hosts nearly 60,000 attendees from around the world.

Relevant Resources

Clinical Trials Update: June 23, 2010

Sun, 27 Jun 2010 17:12:23 +0000

Clinical Trials Update: June 23, 2010
(HealthDay News) — Here are the latest clinical trials, courtesy of ClinicalConnection.com:

Relevant Resources

Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010

Fri, 25 Jun 2010 23:16:29 +0000

Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK:

Read more on PR Newswire via Yahoo! Finance

Relevant Resources

NicOx reports first quarter 2010 financial results

Sat, 08 May 2010 13:13:24 +0000

NicOx reports first quarter 2010 financial results
SOPHIA ANTIPOLIS, FRANCE–(Marketwire – May 7, 2010) – www.nicox.com — NicOx S.A. (NYSE Euronext Paris: COX) today reported financial results for the first three months of 2010 and provided an overview of its activities, in particular those related to its lead compound naproxcinod which is currently under review by the US Food and Drug Administration (FDA) and the …

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System

Sat, 01 May 2010 06:20:37 +0000

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System
MicroCHIPS, Inc., a developer of intelligent implant systems, today announced that it has received a 2010 Edison Best New Product Award for its Illume product. The product was awarded Gold in the Science and Medical Category, recognizing the benefit that it will bring to millions of people with diabetes who must manage their blood sugar intensively to stay healthy.